NCT06731803 (NeoART) is a Phase 1, PHASE2 clinical trial of Trastuzumab deruxtecan + 5FU/LV in Esophagogastric Adenocarcinoma, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

Who is sponsoring NCT06731803?

NCT06731803 is sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

What drugs are being tested in NCT06731803?

Interventions in NCT06731803: Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO.

What condition does NCT06731803 study?

NCT06731803 studies Esophagogastric Adenocarcinoma.

Is NCT06731803 still recruiting?

NCT06731803 is currently recruiting now. Last updated 13 March 2026.

Last reviewed 2026-03-13 · How we verify

NCT06731803: NeoART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Recruiting now Phase 1, PHASE2 Last updated 13 March 2026

What this trial tests

Phase 1, PHASE2 trial testing Trastuzumab deruxtecan + 5FU/LV in Esophagogastric Adenocarcinoma in 36 participants. Currently enrolling.

Timeline

25 March 2025

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	25 March 2025
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	11 locations across Germany

Drugs / interventions tested

Trastuzumab deruxtecan + 5FU/LV — full drug profile →
Trastuzumab deruxtecan + FLO — full drug profile →

Conditions studied

Esophagogastric Adenocarcinoma — all drugs for Esophagogastric Adenocarcinoma →

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full company profile →

Who can join

18 and older, any sex, with Esophagogastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a phase Ib/II, prospective, single arm, open label, non-randomized, multi-center platform trial assessing the feasibility and safety of different neoadjuvant trastuzumab-deruxtecan containing combinational treatment regimens in patients with HER2 positive, locally advanced, resectable esophagogastric adenocarcinoma

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA).
Stocker G, Hacker UT, Obermannová RL, Ilhan-Mutlu A, et al · · 2026 · PMID 42058637 · DOI 10.1016/j.esmogo.2025.100256
Trastuzumab deruxtecan in the treatment of HER2-positive gastric cancer: a comprehensive review.
Jubashi A, Nakayama I, Shitara K. · · 2025 · PMID 41257369 · DOI 10.1080/14796694.2025.2589996

Verify or expand the search:

Other recruiting trials for Esophagogastric Adenocarcinoma

Currently open trials in the same condition.

NCT06623396 — A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer · Phase 1 · recruiting

Other Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials

Trials by the same sponsor.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
NCT07365930 — NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06123468 — Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06731803 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Last refreshed: 13 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06731803.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing